New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Oral Presentation at the 25th European Hematology Association (EHA) Congress 2020/05/14 13:02:06 GlobeNewswire
ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, May 14, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals…
CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue Estimates 2020/04/28 23:45:05 Zacks Investment Research
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -5.50% and -97.53%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate CRISPR Therapeutics AG (CRSP) to Report a Decline in Earnings: What to Look Out for 2020/04/27 16:31:48 Zacks Investment Research
CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Makes CRISPR Therapeutics AG (CRSP) a New Buy Stock 2020/04/27 16:00:06 Zacks Investment Research
CRISPR Therapeutics AG (CRSP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Les biotech helvétiques ont généré près de 5 milliards l’an dernier 2020/04/21 09:45:24 Allnews
La hausse a été alimentée par les revenus des collaborations conclues par AC Immune, Basilea et Crispr Therapeutics, ainsi que par l’accélération des revenus des produits déjà commercialisés.
CRISPR Therapeutics Proposes Changes to the Board of Directors | MarketScreener 2020/02/26 21:06:29 MarketScreener
ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 26, 2020 -- CRISPR Therapeutics , a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today… | February 26, 2020
CRISPR Therapeutics Proposes Changes to the Board of Directors 2020/02/26 21:05:00 GlobeNewswire
ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on…
Global Forecast & Outlook for Crispr Technology, 2021-2026: North America, Europe, Asia-Pacific, Latin America, Africa & Middle East - ResearchAndMarkets.com 2020/02/14 17:31:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "2020 Global Forecast for Crispr Technology (2021-2026 Outlook)-High Tech & Emerging Markets Report" report has been added to ResearchAndMarkets.com's offering. The 2020 Global Forecast for Crispr Technology (2021-2026 Outlook)-High Tech & Emerging Markets Report, contains timely and accurate market statistics and forecasts on the market for over 140 countries. Estimates on equipment or material sales (product shipments value) are published historically for
Stock To Watch: CRISPR Therapeutics (CRSP) 2020/02/13 10:12:00 RTT News
CRISPR Therapeutics AG (CRSP), which is down more than 20% from its yearly high of $74, recorded last December, expects 2020 to have the potential to be a pivotal year in the company's growth.
CRISPR Therapeutics AG (CRSP) Beats Q4 Earnings and Revenue Estimates 2020/02/12 23:55:02 Zacks Investment Research
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 1175.00% and 3.42%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
The Chinese scientist who claims to have edited babies' DNA has been sentenced to 3 years in prison. Here's a timeline of the controversy. 2019/12/30 15:58:00 Business Insider
Chinese scientist He Jiankui, who claims to have made the first genetically edited babies in the world using CRISPR technology, has been sentenced to three years in prison. Many scientists, ethicists, and government officials have criticized He, calling his research unethical and dangerous. After presenting his findings at an international summit in November 2018, He vanished from public view until reports claimed he was being detained at a university guesthouse. On Monday, state media reported that He has been sentenced to three years in prison and faces a $430,000 fine. Two of his colleagues also face prison time. Visit Business Insider's homepage for more stories. In November 2018, a Chinese scientist claimed he had made the first genetically-edited babies in the world, causing sharp criticism from other scientists, ethicists, and government officials. The scientist, He Jiankui, used the gene-editing tool CRISPR-cas9, which is considered risky because it can inadvertently change a large portion of a person's DNA and have unintended consequences.
Chinese scientist who genetically edited babies will spend 3 years in prison 2019/12/30 14:26:48 BGR.com
One of the craziest stories to come out of 2018 was the saga of a Chinese scientist named He Jiankui. The genetics researcher took it upon himself to use the CRISPR gene-editing technique to modify human embryos and then have those embryos carried to term by their mothers. This resulted in what are believed to be the first genetically modified babies ever born. The work sparked immediate criticism from He's peers and the scientific community at large. Scientists around the globe condemned He's work and the Chinese government kept him under strict house arrest while it decided how to proceed. Now, over a year after the experiments were made public, He has received a prison sentence of three years . Three years in prison might sound like a big deal — and, to be fair, it's a significant sentence, especially in the realm of science — but it's a far cry from the punishment some feared He might face. Earlier this year, some of He's colleagues even thought he might face a death penalty for moving forward with his own human gene editing ambitions.
Global CRISPR Technology Market Report 2019-2025 with Analysis of Key Companies - Thermo Fisher Scientific, Merck KGaA, GenScript Biotech, Horizon Discovery Group, CRISPR Therapeutics - ResearchAndMarkets.com 2019/12/05 18:55:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Global CRISPR Technology Market 2019-2025" report has been added to ResearchAndMarkets.com's offering. The global CRISPR technology market is expected to witness a significant growth rate during the forecast period. CRISPR technology enables the alteration of DNA sequences and modifies the gene function. CRISPR technology can be used for various applications such as treatment of diseases, correcting gene, crop modification, bio-fuel manufacturing and many more. Ind
Swiss Health-care Concern out with Big Stock Offering 2019/11/20 19:01:38 Baystreet.ca
Crispr Therapeutics AG (NASDAQ:CRSP) saw its shares drop sharply Wednesday, after reporting a 4.25-million share common stock offering. The Swiss-based biopharmaceutical company, with offices in Cambridge, Mass., focuses on developing transformative …
The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data 2019/11/20 12:25:05 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 19) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Allergan plc (NYSE: AGN )(announced publication of Phase 3 study results of migraine drug candidate) Agenus Inc (NASDAQ: AGEN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares Pharma Inc (NASDAQ: ATRS )(announced a collaboration agreement with Idorsia Pharma for developing a drug-device combo for heart attack) Ardelyx Inc (NASDAQ: ARDX ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Arvinas Inc (NASDAQ: ARVN ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Beigene Ltd (NASDAQ: BGNE ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Cabaletta Bio Inc (NASDAQ: CABA ) CNS Pharmaceuticals Inc (NASDAQ: CNSP )(IPOed Nov. 8) Crispr Therapeutics AG (NASDAQ: CRSP )( announced positive Phase 1/2 results for gene-editing investigational therapy) DexCom, Inc. (NASDAQ: DXCM ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Edwards Lifesciences Corp (NYSE: EW ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Galera Therapeutics Inc (NASDAQ: GRTX )(IPOed Nov.